MoleculaPROVerified Q1 2026
Compressing drug discovery cycles through high-fidelity molecular dynamics and in silico validation.
Technical Benchmark: RBFE (NES-based) <1 kcal/mol; in silico trial scalability.
Venture capital for resilient industrial tech. Strategic management consulting for deep tech startups. In-house digital product incubation. Engineering alpha in biotech R&D. RBFE, DSCSA, agent-native.
Venture & Strategic Advisory
Engineering alpha in frontier tech.
We combine venture capital with strategic advisory to back and scale deep tech companies where technical edge drives durable value.
Investment approach: risk-adjusted value creation in structurally volatile markets; concentration in molecular simulation, synthetic biology, and digital provenance; rigorous operational frameworks for portfolio companies.
Strategic Mission
Convert uncertainty into optionality; build verifiable provenance.
We focus on converting technical uncertainty into priced optionality and designing verifiable provenance architectures that support resilient, self-sustaining value systems across deep tech verticals.
Chekanov Ventures is a deep tech fund focused on risk-adjusted value creation in structurally volatile markets. We back molecular simulation, synthetic biology, and digital provenance platforms that meet regulatory-grade benchmarks, including in silico RBFE accuracy and DSCSA-aligned cryptographic traceability.
Led by leadership with deep tech and venture backgrounds. Full team and fund structure available to qualified allocators upon request.
Portfolio
The venture portfolio
EM PolymerVerified Q1 2026
Establishing resilient plastic degradation systems via engineered enzymes and omics-guided pathway optimization.
Technical Benchmark: Engineered enzymes; omics-guided pathway optimization.
VedaschainVerified Q1 2026
Integrating IoT-blockchain hybrids for immutable supply chain transparency and DAG-based traceability.
Technical Benchmark: DAG-based traceability; ECDSA/EdDSA cryptographic signing.
Tag Trace SystemsVerified Q1 2026
Engineering counterfeit-proof pharmaceutical distribution networks with end-to-end serialization.
Technical Benchmark: DSCSA (US) & EU FMD compliance; pharmaceutical serialization.
Protein ForgeVerified Q1 2026
Computational design of high-utility proteins for industrial applications and advanced material science.
Technical Benchmark: Computational protein design for high-utility industrial applications.
Digital Foundry
Complex Environment Simulations & Agentic IP
The Foundry serves as our internal laboratory for stress-testing high-concurrency architectures. We develop high-fidelity interactive environments that serve as the generative substrate for autonomous agentic logic and independent digital IP.
Foundry Protocol 01
Collapsed latency variance via Rust-based backends; near-zero cold starts for agentic workloads; EdDSA cryptographic signing for digital IP.
Advisory
Operational excellence & value creation
Deployment of proprietary management frameworks to de-risk technical innovation and accelerate market entry.
Systemic architecture
End-to-end R&D pipelines that ensure long-term competitive moats and organizational agility.
Our perspective
How we think
Simulation fidelity
We apply NES-based RBFE (relative binding free energy) protocols achieving <1 kcal/mol error, with in silico trial scalability as the benchmark for molecular dynamics and drug discovery.
Provenance & traceability
ECDSA/EdDSA and DAG-based architectures underpin our view of supply chain integrity and verifiable provenance in regulated industries.
Agentic infrastructure
High-concurrency orchestration, collapsed latency variance, near-zero cold starts, and AI-native CI/CD define our standard for agent-native platforms in the foundry.
Contact
Engagement inquiry
Request introduction
We prioritize strategic alignment over volume. Inquiries are reviewed on technical merit and systemic impact.
Prefer to reach out directly? alexander.chekanov@gmail.com